Adjuvant endocrine therapy and alopecia
A patient on adjuvant endocrine therapy for breast cancer is complaining of hair loss. Could the alopecia be due to her endocrine therapy?
A patient on adjuvant endocrine therapy for breast cancer is complaining of hair loss. Could the alopecia be due to her endocrine therapy?
Can the drug paroxetine mesylate (Brisdelle, Paxil) be given to patients taking a chemoprevention drug such as raloxifene (Evista) or any of the aromatase inhibitors?
Researchers have not only confirmed that tamoxifen induces cognitive dysfunction in users, they have also found an existing treatment that can prevent this adverse effect.
MEK1/2 inhibition rescues glial progenitor cells from toxicity; prevents tamoxifen-induced cell death.
Adding to the picture of what prompts breast cancer to form, researchers have found that distant estrogen response elements can act independently of oncogenes to spur tumor development.
A global study of women with inherited mutations in BRCA1 or BRCA2 found that tamoxifen could halve the risk for breast cancer in the contralateral (opposite-side) breast in these high-risk women.
Clinicians should discuss the prophylactic use of tamoxifen as well as two other agents with women 35 years and older and at increased risk of ER-positive breast cancer, per ASCO recommendations.
The addition of BH3 mimetics to standard tamoxifen treatment improved the effectiveness of hormone therapy in luminal B cancers, an aggressive subtype of ER-positive breast cancer.
A biomarker reflecting expression levels of two genes in tumor tissue has been found to predict which patients may be at risk for late recurrence of estrogen receptor (ER)-positive breast cancer, and when adjuvant letrozole therapy may be of benefit.